萨库比特里尔/瓦尔沙坦对心肌梗塞后痕的抗节律和抗炎作用
Daina Martínez-Falguera1,2, Júlia Aranyó3,4, Albert Teis3
1ICREC Research Program, Germans Trias i Pujol Research Institute, Barcelona, Spain (D.M.-F., G.F.-C., M.M.-T., I.D.-G., S.R., A.B.-G., C.G.-M.).
Circulation. Arrhythmia and electrophysiology
|April 26, 2024
概括
在心肌梗塞 (MI) 后,萨库比特里尔/瓦尔萨坦减少了猪心脏的炎症和纤维化. 这种疗法还降低了心室动脉冲动的诱导性,表明心脏痕重塑得到了改善.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 医学科学 医学科学 医学科学
背景情况:
- 萨库比特里尔/瓦尔沙坦 (Sac/Val) 已因其在心力衰竭管理中的有效性而得到认可.
- 关于Sac/Val对心肌梗塞 (MI) 后心肌痕的影响的机械学数据有限.
研究的目的:
- 研究Sac/Val对炎症,纤维化和电生理学特性在MI后痕重塑中的影响.
- 在猪模型中评估Sac/Val对心室动脉冲动能力的影响.
主要方法:
- 猪MI模型被单独使用β-阻断剂 (BB) 或BB加Sac/Val.治疗.
- 使用了全身免疫反应,心脏磁共振成像,编程电刺激和高密度映射.
- 对心肌样本进行了组织学分析.
主要成果:
- 在MI后,Sac/Val显著降低了急性循环白细胞和介质蛋白-12水平.
- 治疗减少了痕质量,边界区域质量和痕原I含量.
- 静脉动脉动脉高动脉诱导和减速区域在Sac/Val治疗中显著减少.
结论:
- 在MI后,Sac/Val证明了急性系统性炎症标志物的减少.
- Sac/Val 疗法导致总痕和边界区域质量减少.
- 该研究得出结论,Sac/Val降低了心脏病后猪模型中心室动脉冲动的诱导能力.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
496
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
496
Antihypertensive Drugs: Angiotensin II Receptor Blockers
716
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
716
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
980
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
980


